Amy K Otto1, Emily C Soriano2, Scott D Siegel3, Stefanie T LoSavio4, Jean-Philippe Laurenceau5. 1. Department of Psychological and Brain Sciences, University of Delaware, 108 Wolf Hall, Newark, DE, 19716-2577, USA. amy.otto@moffitt.org. 2. Department of Psychological and Brain Sciences, University of Delaware, 108 Wolf Hall, Newark, DE, 19716-2577, USA. 3. Helen F. Graham Cancer Center and Research Institute, 4701 Ogletown Stanton Rd, Newark, DE, 19713, USA. 4. Duke University Medical Center, 1121 W. Chapel Hill St., Ste. 201, Durham, NC, 27701, USA. 5. Department of Psychological and Brain Sciences, University of Delaware, 108 Wolf Hall, Newark, DE, 19716-2577, USA. jlaurenceau@psych.udel.edu.
Abstract
PURPOSE: The purpose of this study was to determine whether fear of cancer recurrence (FCR) is associated with greater health care utilization (HCU) in early-stage breast cancer survivors. METHODS: Three hundred early-stage breast cancer survivors diagnosed within the past 7 years reported on FCR as well as calls and visits to oncology providers and primary care providers during the preceding 3 months. Participants also reported on use of mental health services and psychotropic medications since diagnosis. Structural equation modeling was used to create a latent FCR factor and evaluate this factor as a predictor of various HCU outcomes controlling for age at diagnosis, years since diagnosis, generalized anxiety, objective risk of recurrence, and number of comorbidities. RESULTS: FCR predicted more visits to both oncology providers (RR = 1.53, p = .002) and primary care providers (RR = 1.31, p = .013), as well as more phone calls to oncology providers (RR = 2.08, p = .007). FCR was not a significant predictor of phone calls to primary care providers (RR = 1.39, p = .054), utilization of mental health treatment (OR = 1.27, p = .362), or use of psychotropic medications (OR = 1.37, p = .178). CONCLUSIONS: FCR was associated with increases in some types of HCU, which may reflect excessive medical reassurance-seeking and lead to unnecessary medical costs. IMPLICATIONS FOR CANCER SURVIVORS: FCR is a serious concern that warrants greater attention to reduce distress-related health care utilization. Utilization of mental health services to address FCR may represent higher-value health care.
PURPOSE: The purpose of this study was to determine whether fear of cancer recurrence (FCR) is associated with greater health care utilization (HCU) in early-stage breast cancer survivors. METHODS: Three hundred early-stage breast cancer survivors diagnosed within the past 7 years reported on FCR as well as calls and visits to oncology providers and primary care providers during the preceding 3 months. Participants also reported on use of mental health services and psychotropic medications since diagnosis. Structural equation modeling was used to create a latent FCR factor and evaluate this factor as a predictor of various HCU outcomes controlling for age at diagnosis, years since diagnosis, generalized anxiety, objective risk of recurrence, and number of comorbidities. RESULTS: FCR predicted more visits to both oncology providers (RR = 1.53, p = .002) and primary care providers (RR = 1.31, p = .013), as well as more phone calls to oncology providers (RR = 2.08, p = .007). FCR was not a significant predictor of phone calls to primary care providers (RR = 1.39, p = .054), utilization of mental health treatment (OR = 1.27, p = .362), or use of psychotropic medications (OR = 1.37, p = .178). CONCLUSIONS: FCR was associated with increases in some types of HCU, which may reflect excessive medical reassurance-seeking and lead to unnecessary medical costs. IMPLICATIONS FOR CANCER SURVIVORS: FCR is a serious concern that warrants greater attention to reduce distress-related health care utilization. Utilization of mental health services to address FCR may represent higher-value health care.
Entities:
Keywords:
Breast cancer; Fear of recurrence; Health anxiety; Health care utilization; Medical reassurance-seeking; Survivorship concerns
Authors: William R Hendee; Gary J Becker; James P Borgstede; Jennifer Bosma; William J Casarella; Beth A Erickson; C Douglas Maynard; James H Thrall; Paul E Wallner Journal: Radiology Date: 2010-08-24 Impact factor: 11.105
Authors: James L Khatcheressian; Patricia Hurley; Elissa Bantug; Laura J Esserman; Eva Grunfeld; Francine Halberg; Alexander Hantel; N Lynn Henry; Hyman B Muss; Thomas J Smith; Victor G Vogel; Antonio C Wolff; Mark R Somerfield; Nancy E Davidson Journal: J Clin Oncol Date: 2012-11-05 Impact factor: 44.544
Authors: Julie M Cessna Palas; Kelly A Hyland; Ashley M Nelson; Brent J Small; Heather S L Jim; Paul B Jacobsen Journal: Support Care Cancer Date: 2020-06-10 Impact factor: 3.603
Authors: Emily C Soriano; Amy K Otto; Stefanie T LoSavio; Christine Perndorfer; Scott D Siegel; Jean-Philippe Laurenceau Journal: Ann Behav Med Date: 2021-03-20
Authors: Lidia Schapira; Yue Zheng; Shari I Gelber; Philip Poorvu; Kathryn J Ruddy; Rulla M Tamimi; Jeffrey Peppercorn; Steven E Come; Virginia F Borges; Ann H Partridge; Shoshana M Rosenberg Journal: Cancer Date: 2021-10-06 Impact factor: 6.921
Authors: Eric Vachon; Ellen Krueger; Victoria L Champion; David A Haggstrom; David Cella; Andrea A Cohee Journal: Psychooncology Date: 2020-10-15 Impact factor: 3.894
Authors: Lynne I Wagner; Janet A Tooze; Daniel L Hall; Beverly J Levine; Jennifer Beaumont; Jenna Duffecy; David Victorson; William Gradishar; Joseph Leach; Thomas Saphner; Keren Sturtz; Mary Lou Smith; Frank Penedo; David C Mohr; David Cella Journal: J Natl Cancer Inst Date: 2021-11-02 Impact factor: 11.816
Authors: Ulrike Boehmer; Jennifer Potter; Melissa A Clark; Al Ozonoff; Michael Winter; Flora Berklein; Kevin C Ward; Kevan Hartshorn Journal: Support Care Cancer Date: 2021-03-19 Impact factor: 3.359
Authors: Florie E Van Beek; Lonneke M A Wijnhoven; Karen Holtmaat; José A E Custers; Judith B Prins; Irma M Verdonck-de Leeuw; Femke Jansen Journal: Psychooncology Date: 2021-07-06 Impact factor: 3.955